Welcome to LookChem.com Sign In|Join Free
  • or
3-Pyridinemethanamine,2,6-dimethyl-(9CI) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

672325-49-4

Post Buying Request

672325-49-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

672325-49-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 672325-49-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,7,2,3,2 and 5 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 672325-49:
(8*6)+(7*7)+(6*2)+(5*3)+(4*2)+(3*5)+(2*4)+(1*9)=164
164 % 10 = 4
So 672325-49-4 is a valid CAS Registry Number.

672325-49-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name (2,6-dimethylpyridin-3-yl)methanamine

1.2 Other means of identification

Product number -
Other names 3-pyridinemethanamine,2,6-dimethyl

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:672325-49-4 SDS

672325-49-4Downstream Products

672325-49-4Relevant academic research and scientific papers

CANCER TREATMENTS TARGETING CANCER STEM CELLS

-

Paragraph 0331; 0402-0404; 0407; 0410-0411, (2019/11/19)

Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. The compounds utilized in the disclosure are of Formula (0), (O'), and (I):

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

-

Page/Page column 50; 51, (2014/09/29)

The present invention is directed to substituted pyridizinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

-

Page/Page column 51, (2014/10/04)

The present invention is directed to substituted pyridizinone compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 672325-49-4